FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

By Rene Pretorius

January 24, 2025

The FDA approved datopotamab deruxtecan (Datroway) for adults with unresectable or metastatic, hormone receptor (HR)-positive, HER2-negative breast cancer. Patients must have received prior endocrine-based therapy and chemotherapy. The approval is based on the TROPION-Breast01 trial, which showed improved progression-free survival (PFS) compared to chemotherapy.

Key Insights

  • Efficacy: The TROPION-Breast01 trial showed datopotamab deruxtecan significantly improved PFS. The median PFS was 6.9 months versus 4.9 months for chemotherapy (Hazard ratio 0.63, p < 0.0001).
  • Safety: Common side effects included stomatitis, nausea, fatigue, and laboratory abnormalities like decreased leukocytes and hemoglobin.
  • Patient Population: The drug is for patients with disease progression who cannot continue endocrine therapy. Eligible patients must have received one or two prior lines of chemotherapy for unresectable or metastatic disease.
  • Dosage: The recommended dose is 6 mg/kg (maximum 540 mg for patients ≥90 kg), given as an intravenous infusion every three weeks.

Background Context

  • Breast Cancer Subtypes: HR-positive, HER2-negative breast cancer is common. Treatments like datopotamab deruxtecan target specific molecular features. The FDA’s approval aligns with ongoing efforts to develop more targeted therapies.
  • Clinical Trials: The TROPION-Breast01 trial was a multicenter, open-label, randomized study. This design is crucial for evaluating cancer treatments and is often referenced by organizations like the FDA and the National Cancer Institute (NCI).

Implications

  • Health Economics: The approval could impact healthcare costs and resource allocation. Targeted therapies can be expensive but may reduce long-term costs by improving outcomes and lowering the need for additional treatments.
  • Health Outcomes: Better PFS and overall survival can enhance patients’ quality of life. This approval may also encourage further research into targeted cancer therapies.
  • Clinical Practice: Datopotamab deruxtecan introduces a new option for treating HR-positive, HER2-negative breast cancer. It offers healthcare providers another choice for patients who have exhausted other treatments, potentially improving personalized treatment strategies.

 

This approval highlights the role of innovative treatments in improving patient outcomes and potentially reducing healthcare costs. Ongoing research and clinical trials remain crucial for developing and evaluating new therapies.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...